Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

Inclusion Criteria: * Documented disease progression during imatinib and sunitinib therapy OR intolerance to imatinib and/or sunitinib * At least one measurable site of disease on CT/MRI scan * PS≤2 * Normal organ, electrolyte, and bone marrow function Exclusion Criteria: * Previous treatment with nilotinib or any other drug in this class or other targeted therapy * Treatment with any cytotoxic and/or investigational drug ≤ 4 weeks prior to study entry * Impaired cardiac function * Use of coumarin derivatives (i.e. warfarin) * Women who are pregnant or lactating Other protocol-defined inclusion/exclusion criteria may apply.